With regards to providing a treatment for OSA, the only real "solution" presently is the CPAP machine and Resmed has a monopoly in that market; they are currently valued at $10.2 billion (annual revenue of $AUD 3.88 billion). I know they're involved in a few other things but this is their primary source of revenue.
We can probably let our imaginations run wild when trying to predict what the market will value a successful OSA trial at based on these numbers
- Forums
- ASX - By Stock
- IHL
- Share your ideas and thoughts.
Share your ideas and thoughts., page-425
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
BTH
BIGTINCAN HOLDINGS LIMITED
David Keane, Co-Founder & CEO
David Keane
Co-Founder & CEO
Previous Video
Next Video
SPONSORED BY The Market Online